Market Forecast By Biomarkers Type (Protein Biomarkers, Genetic Biomarkers, Other Cancer Biomarkers), By Cancer Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, Leukemia, Thyroid Cancer, Bladder Cancer), By Profiling Technologies (Omics Technologies, Imaging Technologies, Immunoassay, Bioinformatics, Cytogenetics), By Application (Diagnostics, Research & Development, Prognostics, Risk Assessment, Other Applications) And Competitive Landscape
| Product Code: ETC4471716 | Publication Date: Jul 2023 | Updated Date: Aug 2025 | Product Type: Report | |
| Publisher: 6Wresearch | Author: Dhaval Chaurasia | No. of Pages: 85 | No. of Figures: 45 | No. of Tables: 25 |
| Report Name | Australia Cancer Biomarkers Market |
| Forecast Period | 2024-2030 |
| CAGR | 8.9% |
| Growing Sector | Healthcare |
The Australia Cancer Biomarkers Market report thoroughly covers the market by Biomarkers type, by cancer type, by profiling technologies and by application. The Australia Cancer Biomarkers market report provides an unbiased and detailed analysis of the ongoing market trends, opportunities/high growth areas, and market drivers which would help the stakeholders to devise and align their market strategies according to the current and future market dynamics.
The Australia Cancer Biomarkers Market Report provides insights into the use of biomarkers in Australia for cancer diagnosis and treatment. It emphasizes the importance of biomarkers in tailoring drug prescriptions to patients with specific tumor targets, thereby avoiding unnecessary side effects and costs. the report discusses the role of biomarkers in personalized medicine and the challenges and opportunities associated with their use in improving patient care and outcomes.
According to 6Wresearch, the Australia Cancer Biomarkers Market size is expected to grow at a CAGR of 8.9% during 2024-2030. The drivers of the cancer biomarkers market in Australia include the increasing prevalence of cancer worldwide, the growing importance of companion diagnostics, continuous product innovations, and advancements in biomarker technologies. These factors contribute to the market's growth by enhancing personalized medicine, improving drug discovery, and supporting better patient outcomes. However, the market faces some challenges such as high capital investments required for biomarker development, lengthy timelines for validation, regulatory uncertainties, and concerns about return on investment for biomarkers. Additionally, the lack of standardized regulatory frameworks and the evolving nature of digital biomarkers pose obstacles to market growth
In the cancer biomarkers market in Australia, some of the major players include Abbott Laboratories Inc., Thermo Fisher Scientific, Agilent Technologies, Biomerieux SA, and Celera Corporation (Quest Diagnostics). These companies are actively involved in research and development, market expansions, partnerships, and mergers to drive growth and innovation in the field of cancer biomarkers in Australia.
The government plays a crucial role in regulating the use of cancer biomarkers in Australia. In order to ensure patient safety and promote ethical use of biomarkers, several regulatory bodies have been established. One such body is the Therapeutic Goods Administration (TGA), which is responsible for regulating all therapeutic goods including cancer biomarkers. The TGA assesses the quality, safety and efficacy of biomarkers before they are approved for use in Australia. This ensures that only high-quality and safe biomarkers are available in the market.
The future insights of the cancer biomarkers market in Australia include the increasing importance of biomarkers in tailoring drug prescriptions to patients with specific tumor targets, thereby enhancing personalized medicine and improving patient outcomes. Biomarkers will enable drugs to be prescribed more specifically, avoiding unnecessary side effects and costs for patients unlikely to benefit from certain treatments. Standardizing methods for assessing biomarker efficacy and developing regulatory frameworks for biomarker testing approval and funding will be essential for optimizing their use in Australia.
According to Dhaval, Research Manager, 6Wresearch, Protein biomarkers are currently the most prominent type of cancer biomarker being used in Australia. These biomarkers have a wide range of applications in both early detection and monitoring of cancer treatments. The rising prevalence of various types of Cancer and the increasing demand for personalized medicine have led to the growth of this segment.
The market for breast cancer biomarkers is expected to witness the highest growth in Australia. This can be attributed to various factors such as increasing awareness about breast cancer, advancements in diagnostic techniques, and government initiatives promoting early detection and treatment of breast cancer. Breast cancer is the leading cause of cancer deaths among women in Australia and hence, there is a growing demand for effective biomarkers for its early detection.
The diagnostics segment holds the largest share in the Australian cancer biomarkers market due to the increasing number of breast cancer cases and government initiatives promoting early detection. According to Cancer Australia, breast cancer is estimated to be the most commonly diagnosed cancer among Australian women in 2021. Additionally, advancements in technology have led to the development of more accurate and less invasive diagnostic tests using biomarkers, further driving the growth of this segment
The report offers a comprehensive study of the subsequent market segments:
| 1 Executive Summary |
| 2 Introduction |
| 2.1 Key Highlights of the Report |
| 2.2 Report Description |
| 2.3 Market Scope & Segmentation |
| 2.4 Research Methodology |
| 2.5 Assumptions |
| 3 Australia Cancer Biomarkers Market Overview |
| 3.1 Australia Country Macro Economic Indicators |
| 3.2 Australia Cancer Biomarkers Market Revenues & Volume, 2021 & 2031F |
| 3.3 Australia Cancer Biomarkers Market - Industry Life Cycle |
| 3.4 Australia Cancer Biomarkers Market - Porter's Five Forces |
| 3.5 Australia Cancer Biomarkers Market Revenues & Volume Share, By Biomarkers Type, 2021 & 2031F |
| 3.6 Australia Cancer Biomarkers Market Revenues & Volume Share, By Cancer Type, 2021 & 2031F |
| 3.7 Australia Cancer Biomarkers Market Revenues & Volume Share, By Profiling Technologies, 2021 & 2031F |
| 3.8 Australia Cancer Biomarkers Market Revenues & Volume Share, By Application, 2021 & 2031F |
| 4 Australia Cancer Biomarkers Market Dynamics |
| 4.1 Impact Analysis |
| 4.2 Market Drivers |
| 4.2.1 Increasing prevalence of cancer in Australia |
| 4.2.2 Growing adoption of personalized medicine |
| 4.2.3 Technological advancements in biomarker development |
| 4.3 Market Restraints |
| 4.3.1 Stringent regulatory requirements for biomarker approval |
| 4.3.2 High cost associated with biomarker development and testing |
| 4.3.3 Limited reimbursement policies for biomarker-based diagnostics |
| 5 Australia Cancer Biomarkers Market Trends |
| 6 Australia Cancer Biomarkers Market, By Types |
| 6.1 Australia Cancer Biomarkers Market, By Biomarkers Type |
| 6.1.1 Overview and Analysis |
| 6.1.2 Australia Cancer Biomarkers Market Revenues & Volume, By Biomarkers Type, 2021-2031F |
| 6.1.3 Australia Cancer Biomarkers Market Revenues & Volume, By Protein Biomarkers, 2021-2031F |
| 6.1.4 Australia Cancer Biomarkers Market Revenues & Volume, By Genetic Biomarkers, 2021-2031F |
| 6.1.5 Australia Cancer Biomarkers Market Revenues & Volume, By Other Cancer Biomarkers, 2021-2031F |
| 6.2 Australia Cancer Biomarkers Market, By Cancer Type |
| 6.2.1 Overview and Analysis |
| 6.2.2 Australia Cancer Biomarkers Market Revenues & Volume, By Breast Cancer, 2021-2031F |
| 6.2.3 Australia Cancer Biomarkers Market Revenues & Volume, By Lung Cancer, 2021-2031F |
| 6.2.4 Australia Cancer Biomarkers Market Revenues & Volume, By Colorectal Cancer, 2021-2031F |
| 6.2.5 Australia Cancer Biomarkers Market Revenues & Volume, By Prostate Cancer, 2021-2031F |
| 6.2.6 Australia Cancer Biomarkers Market Revenues & Volume, By Melanoma, 2021-2031F |
| 6.2.7 Australia Cancer Biomarkers Market Revenues & Volume, By Leukemia, 2021-2031F |
| 6.2.8 Australia Cancer Biomarkers Market Revenues & Volume, By Bladder Cancer, 2021-2031F |
| 6.2.9 Australia Cancer Biomarkers Market Revenues & Volume, By Bladder Cancer, 2021-2031F |
| 6.3 Australia Cancer Biomarkers Market, By Profiling Technologies |
| 6.3.1 Overview and Analysis |
| 6.3.2 Australia Cancer Biomarkers Market Revenues & Volume, By Omics Technologies, 2021-2031F |
| 6.3.3 Australia Cancer Biomarkers Market Revenues & Volume, By Imaging Technologies, 2021-2031F |
| 6.3.4 Australia Cancer Biomarkers Market Revenues & Volume, By Immunoassay, 2021-2031F |
| 6.3.5 Australia Cancer Biomarkers Market Revenues & Volume, By Bioinformatics, 2021-2031F |
| 6.3.6 Australia Cancer Biomarkers Market Revenues & Volume, By Cytogenetics, 2021-2031F |
| 6.4 Australia Cancer Biomarkers Market, By Application |
| 6.4.1 Overview and Analysis |
| 6.4.2 Australia Cancer Biomarkers Market Revenues & Volume, By Diagnostics, 2021-2031F |
| 6.4.3 Australia Cancer Biomarkers Market Revenues & Volume, By Research & Development, 2021-2031F |
| 6.4.4 Australia Cancer Biomarkers Market Revenues & Volume, By Prognostics, 2021-2031F |
| 6.4.5 Australia Cancer Biomarkers Market Revenues & Volume, By Risk Assessment, 2021-2031F |
| 6.4.6 Australia Cancer Biomarkers Market Revenues & Volume, By Other Applications, 2021-2031F |
| 7 Australia Cancer Biomarkers Market Import-Export Trade Statistics |
| 7.1 Australia Cancer Biomarkers Market Export to Major Countries |
| 7.2 Australia Cancer Biomarkers Market Imports from Major Countries |
| 8 Australia Cancer Biomarkers Market Key Performance Indicators |
| 8.1 Number of clinical trials incorporating cancer biomarkers |
| 8.2 Adoption rate of biomarker-based diagnostic tests in cancer treatment |
| 8.3 Investment in research and development of new cancer biomarkers. |
| 9 Australia Cancer Biomarkers Market - Opportunity Assessment |
| 9.1 Australia Cancer Biomarkers Market Opportunity Assessment, By Biomarkers Type, 2021 & 2031F |
| 9.2 Australia Cancer Biomarkers Market Opportunity Assessment, By Cancer Type, 2021 & 2031F |
| 9.3 Australia Cancer Biomarkers Market Opportunity Assessment, By Profiling Technologies, 2021 & 2031F |
| 9.4 Australia Cancer Biomarkers Market Opportunity Assessment, By Application, 2021 & 2031F |
| 10 Australia Cancer Biomarkers Market - Competitive Landscape |
| 10.1 Australia Cancer Biomarkers Market Revenue Share, By Companies, 2024 |
| 10.2 Australia Cancer Biomarkers Market Competitive Benchmarking, By Operating and Technical Parameters |
| 11 Company Profiles |
| 12 Recommendations |
| 13 Disclaimer |